KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Debt (2018 - 2022)

TherapeuticsMD (TXMD) has disclosed Total Debt for 7 consecutive years, with $93.6 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Total Debt fell 49.88% year-over-year to $93.6 million, compared with a TTM value of $93.6 million through Sep 2022, down 49.88%, and an annual FY2021 reading of $188.3 million, down 20.79% over the prior year.
  • Total Debt was $93.6 million for Q3 2022 at TherapeuticsMD, up from $90.8 million in the prior quarter.
  • Across five years, Total Debt topped out at $243.8 million in Q2 2020 and bottomed at $73.1 million in Q2 2018.
  • Average Total Debt over 5 years is $165.0 million, with a median of $187.5 million recorded in 2021.
  • The sharpest move saw Total Debt surged 231.19% in 2020, then tumbled 51.0% in 2022.
  • Year by year, Total Debt stood at $73.4 million in 2018, then surged by 165.24% to $194.6 million in 2019, then rose by 22.13% to $237.7 million in 2020, then dropped by 20.79% to $188.3 million in 2021, then crashed by 50.28% to $93.6 million in 2022.
  • Business Quant data shows Total Debt for TXMD at $93.6 million in Q3 2022, $90.8 million in Q2 2022, and $202.9 million in Q1 2022.